Serum amyloid A (SAA)

Serum amyloid A (SAA) is a family of highly conserved apolipoproteins primarily synthesized by the liver during the acute-phase response. In humans, the group includes inducible isoforms SAA1 and SAA2, which can increase up to 1000-fold in response to inflammatory cytokines like IL-6 and TNF-alpha, and a constitutive isoform SAA4. Beyond its role as a clinical biomarker for systemic inflammation, SAA acts as a potent immunomodulator by recruiting leukocytes through receptors like FPR2 and TLR2 and inducing the production of pro-inflammatory cytokines and matrix-degrading enzymes. Chronic elevation of SAA is the causative factor in AA amyloidosis, where SAA fragments deposit as insoluble fibrils in organs, leading to progressive failure, particularly in the kidneys. Therapeutic strategies targeting SAA include small-molecule inhibitors of fibrillogenesis, neutralizing monoclonal antibodies, and upstream cytokine blockers that reduce its production.

Other names

SAA1SAA2SAA4Acute-phase serum amyloid AA-SAAConstitutive serum amyloid AC-SAAAmyloid fibril protein AAApolipoprotein SAAPIG4TP53I4

Competitive binding to glycosaminoglycan-binding sites on SAA to inhibit fibril polymerization and amyloid deposition; neutralization of pro-inflammatory signaling via receptor blockade; and suppression of hepatic SAA synthesis through the inhibition of upstream cytokines such as IL-6 and TNF-alpha.